57.30
+2.69%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bionime
Its shares trade on Taiwan Stock Exchange under the ticker 4737.TW. It has been listed since 26 August 2009. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.84bn and a net loss of TWD 180.3m. At that date it held total assets of TWD 5.70bn and shareholders' equity of TWD 1.75bn.
Bionime Corp. engages in the production and sale of medical test devices. The company is headquartered in Taichung, Taichung. The company went IPO on 2009-08-26. The firm's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The firm distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 26 Aug 2009
- Website
- bionime.com ↗
Leadership
Pay as last reported
- Chun HuangChairman of the Board, General Manager, since 2003
- Taixiong JiangDeputy General Manager-Administration, Director, since 2007
- Shixiong HuangDeputy General Manager
- Mr. Zhenteng XuDeputy General Manager-R&D
- Xiexun ZhongExecutive Deputy General Manager
- Yawen ChenActing Head of Accounting
- Qianyu HuangHead of Finance
- Wei TangCorporate Governance Officer
- Liren HuDirector
- Ms. Hsiu-Mei LiuDirector
- Ganren CaiIndependent Director
- Lizhen GuoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bionime Corp has several strengths that contribute to its success. Firstly, the company has a strong reputation and brand image in the healthcare industry. This positive perception helps to attract customers and business partners. Moreover, Bionime Corp has a diverse portfolio of innovative and high-quality medical devices, including blood glucose monitoring systems and other diagnostic products. These cutting-edge technologies provide a competitive edge and position the company as a leader in the market. Additionally, Bionime Corp has a highly skilled and experienced workforce, enabling effective execution of its operations and the ability to develop industry-leading products.
Weaknesses
- Despite its strengths, Bionime Corp does face certain weaknesses. One significant weakness is the company's limited geographical reach. Bionime Corp primarily operates in specific regions and may not have a strong presence in other markets. This limited market penetration potentially restricts the company's growth opportunities. Furthermore, Bionime Corp's heavy reliance on a few key suppliers for crucial components or materials exposes them to supply chain risks and potential disruptions. Addressing these weaknesses is crucial for the company's long-term success.
Opportunities
- Bionime Corp operates in an industry with several growth opportunities. Firstly, with the increasing prevalence of chronic diseases globally, the demand for accurate diagnostic tools such as blood glucose monitoring systems is expected to rise. Bionime Corp can capitalize on this trend by expanding its market presence and introducing new products to cater to emerging markets. Additionally, advancements in healthcare technologies and the rising adoption of telemedicine provide opportunities for Bionime Corp to develop innovative solutions that integrate with digital health platforms. By embracing these opportunities, the company can achieve significant growth and enhance its competitive position.
Threats
- Bionime Corp faces several threats that could impact its business. An ongoing challenge is fierce competition from other well-established healthcare companies that also offer blood glucose monitoring systems and related products. This competitive landscape puts pressure on Bionime Corp to continuously innovate and differentiate itself from rivals. Additionally, stringent regulatory requirements in the healthcare industry can create barriers to market entry and product development. Compliance with these regulations can be costly and time-consuming. Lastly, economic fluctuations and uncertainties, such as recessions or changes in healthcare policies, pose risks to Bionime Corp's revenue and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.